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Abstract
Background/Aim. In recent years, the focus of interest of
the scientific community is the application of heart markers
as early indicators and prognostic parameters of perinatal
asphyxia (PA). The aim of this study was to evaluate the
significance of clinical application of heart markers in term
newborns with perinatal asphyxia. Methods. During a 3-
year period we analyzed 91 full-term newborns (55 with and
36 without perinatal asphyxia). In all the subjects within the
first 24–48 h after birth, we simultaneously determined se-
rum concentrations of cardiac troponin I, brain natriuretic
peptide, MB fraction of creatine kinase (CK-MB) and C-
reactive protein. Results. In the group of full-term neo-
nates with PA significantly higher levels of cardiac tropon-
inI (p = 0.000), CK-MB fraction (p = 0.000), brain natriu-
retic peptide (p = 0.003) and C-reactive protein (p = 0.017)
were found, compared to the group of healthy full-term
newborns. In merged group (n = 91) cardiac troponin I
level correlated with the fifth minute Apgar score (r = -
0.637, p = 0.000) and the serum lactate concentration in the
first 12h after birth (r = 0.529, p = 0.000). Early increase in
cardiac troponin I > 0.135 μg/L predicted the risk of death
with the sensitivity of 84.6% and specificity of 85.9%, while
the increase in CK-MB fraction, brain natriuretic peptide
and  C-reactive protein did not have a predictive value with
respect to a mortality outcome. Conclusion. Among the
tested cardiac markers, cardiac troponin I is the most sensi-
tive and the only reliable early predictor of mortality in full-
term neonates with perinatal asphyxia.
Key words:
perinatology; asphyxia; biological markers; heart
failure; troponin I; sensitivity and specificity.
Apstrakt
Uvod/Cilj. Poslednjih godina u žiži interesovanja nauÿne
javnosti je primena srÿanih markera kao ranih indikatora i
prognostiÿkih parametara perinatalne asfiksije. Cilj ovog
rada bio je da se proceni znaÿaj kliniÿke primene srÿanih
markera kod terminske novoroĀenÿadi sa perinatalnom as-
fiksijom. Metode. Tokom trogodišnje studije analizirano
je 91 terminsko novoroĀenÿe (55 sa i 36 bez perinatalne
asfiksije). Kod svih ispitanika odreĀivana je simultano se-
rumska koncentracija srÿanog troponina-I, moždanog nat-
riuretskog peptida, MB frakcije kreatin kinaze i C-
reaktivnog proteina u prvih 24–48 h po roĀenju. Rezulta-
ti. U grupi terminske novoroĀenÿadi sa perinatalnom asfi-
ksijom registrovan je znaÿajno viši nivo srÿanog troponi-
na-I (p = 0,000), CK-MB frakcije (p = 0,000), moždanog
natriuretskog peptida (p = 0,003) i C-reaktivnog proteina
(p = 0,017), u odnosu na grupu zdrave, terminske novoro-
Āenÿadi. Nivo srÿanog troponina-I bio je u korelaciji sa
Apgar skorom u petom minutu (r = -0,637; p = 0,000) i
koncentracijom laktata u prvih 12 h po roĀenju (r = 0,529;
p = 0,000). Rani porast srÿanog troponina-I > 0,135 μg/L
ukazivao je na rizik od smrtnog ishoda, sa senzitivnošýu
84,6% i specifiÿnošýu 85,9%, dok porast CK-MB frakcije,
moždanog natriuretskog peptida i C-reaktivnog proteina
nije bio pouzdan prediktor mortaliteta. Zakljuÿak. Srÿani
troponin-I je najsenzitivniji i jedini pouzdan prediktor
mortaliteta kod terminske novoroĀenÿadi sa perinatalnom
asfiksijom.
Kljuÿne reÿi:
perinatologija; gušenje; biološki pokazatelji; srce,
insuficijencija; troponin I; testovi, prognostiÿka
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Introduction
Three groups of cardiac markers are routinely used in
adult clinical cardiology: markers of cardiac function, mark-
ers of necrosis and inflammation markers 
1. Markers of car-
diac function (cardiac natriuretic peptides) are used in diagno-
sis, monitoring, prognosis and treatment of heart failure 
1, 2.
Markers of myocyte necrosis, cardiac troponin I (cTnI) and
cardiac troponin T (cTnT), are included in the new interna-
tional guidelines for diagnosis and treatment of acute myo-
cardial infarction 
1, 3. Markers of inflammation, particularly
C-reactive protein (CRP), play an important role in risk
stratification and application of appropriate therapy in acute
coronary syndrome 
1, 4.
Acute coronary syndrome (ACS) refers to a spectrum of
clinical presentations ranging from unstable angina, to non-
ST-segment elevation myocardial infarction (NSTEMI) and,
finally, to ST-segment elevation myocardial infarction
(STEMI). Patients with unstable angina can be separated
from those with NSTEMI by measuring the levels of tro-
ponin as cardiac-specific markers which can reveal minimal
(microscopic) myocardial necrosis. With that in mind, it is of
paramount importance to determine troponin reference val-
ues 㻌 㻌 and detection limits, which is the subject of extensive
evaluation and standardization at the international level 
5.
The application of biochemical markers in perinatal as-
phyxia (PA) has not been sufficiently studied in the litera-
ture. McAuliffe et al. 
6 in the study of 110 infants, mean
gestational age of 39.9 weeks (33.4–42.3 weeks), were ana-
lyzed for cTnI levels and correlated with intrapartal risk
factors and blood pH levels. These authors found a signifi-
cant difference in the level of cTnI in the observed groups. In
84/110 (76%) of the newborns they found the mean value
(median) of cTnI to be 0.03 ng/mL (0.03–0.881 ng/mL) and
in 26/110 (23.6%) it was 0.5 ng/mL (0.00–4.3 ng/mL). Also,
they found that 90 percentile for healthy neonatal population
represents the value of cTnI < 0.05 ng/mL, reported in
12/110 (10.9%) of respondents, on the basis of their results.
In 5/110 (4.5%) of respondents in this study, the cTnI value
was registered > 0.1 ng/ml, which according to the reference
values 㻌 㻌 for adults, might indicate cardiac morbidity and sig-
nificant consequences. Comparing the group of patients with
normal and high concentrations of cTnI, McAuliffe et al. 
6
noted significantly lower blood pH (7.24 ± 0.09) in the pa-
tients with intrapartal risk factors and high levels of serum
cTnI, compared with the group of healthy term newborns
(pH = 7.32 ± 0.07). The results of these and other authors
suggested that troponin I could be used as early indicator of
PA 
6–10.
Most of the neonatal studies are focused on changes in
serum concentrations of cardiac troponins (cTnI/cTnT) and
natriuretic peptides (BNP/NT-pro-BNP) with respect to ges-
tational age, patent ductus arteriosus, degree of respiratory
distress syndrome and/or perinatal asphyxia, applied venti-
latory, inotropic and other therapies. It was found that the in-
crease in these biochemical markers was often in proportion
with the diameter of patent ductus arteriosus, degree of respi-
ratory distress syndrome and perinatal asphyxia, hypoxic is-
chemic encephalopathy and other serious conditions which
are the cause of significant mortality and long-term morbid-
ity 
7, 11–18.
In adult patients with chronic heart failure, increased
levels of cardiac troponins or BNP / NT-pro-BNP have a
prognostic significance. High values 㻌 㻌 of these biomarkers
were demonstrated to be associated with higher mortality and
higher rates of repeated hospitalizations 
1, 3, 19–22. Elevated
levels of these biomarkers in acute coronary syndrome were
also associated with increased mortality and increased inci-
dence of recurrent ischemic events
 23, 24.
In neonatal studies, increased BNP / NT-pro-BNP lev-
els, as markers of heart failure, positively correlated with
elevated levels of serum troponins as markers of myocyte
necrosis, indicating severe myocardial damage with possible
fatal outcome
 13.
C-reactive protein is a highly sensitive but not a specific
marker of acute inflammation 
4, 25. In newborn infants infec-
tion is a common cause of neonatal morbidity and mortality.
Early and rapid diagnosis of systemic infection is very im-
portant for the timely treatment, and the role of CRP, as an
early marker of inflammation, is very important. On the
other hand, a well-known prognostic significance of in-
creased CRP levels in adults with coronary ischemia open
the discussion on the possibilities of implementing CRP as a
prognostic marker of post-asphyctic myocardial lesions in
newborns 
25.
The aim of this study was to assess whether there is a
significant difference in serum cardiac troponin I, creatine
kinase MB fraction, brain natriuretic peptide and CRP be-
tween the groups of term neonates, with and without PA. The
aim of this study was also to precisely determine the predic-
tive value of each of the above mentioned biomarkers with
respect to fatal outcome in the examined group of term new-
borns with PA.
Methods
This study was conducted at the Center of Neonatology,
Pediatric Clinic and Maternity Gynecology and Obstetrics
Clinic, Clinical Centre Kragujevac, during the period August
2007 – January 2010. The study was retrospective-
prospective and non-interventional. Not a single diagnostic
procedure was performed solely for the purpose of the study
but was conducted within the framework of referent neonatal
protocols and was approved both by the parents written con-
sent, and the Ethics Committee, Clinical Center in Kra-
gujevac, No. 01-613.
A previously conducted pilot study, determined that to
get a statistically significant difference in the level of tro-
ponin I compared to the group of neonates without PA
(power of the study 80%,  statistical significance 0.05), the
minimal number of examinees in the group of neonates with
PA was 36.
During a 3-year study we analyzed 108 subjects, 17
neonates were excluded from the study. Exclusion criteria
were: proven congenital heart defect (1 hypoplastic left heart
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stenosis and 2 atrial septal defects), chromosomal aberrations
(1 Edwards and 2 Downs syndrome), and conatal sepsis (9
patients with positive blood cultures).
The study included a total of 91 full-term neonates (55
with and 36 without perinatal asphyxia). The clinical diagno-
sis of PA was based on the criteria Caliskan et al. 
12 and Zu-
pan Simunek 
26.
Inclusion criteria for the study were: the history of fetal
asphyxia and gynecology/obstetric complications; cardiores-
piratory and neurological depression defined by Apgar score
< 4 in the 1st minute and < 7 in the 5th minute after delivery;
metabolic acidosis (defined as a lactate level > 3.7 mmol/L
in the first 1–12 hours after birth); respiratory distress; con-
vulsions, coma or hypotonia in the first 48 h after birth; hy-
potension and/or oliguria; multiorgan failure.
Following variables were analyzed in both the groups
of examinees: the 5th minute Apgar score; blood lactate lev-
els in the first 1–12 h after birth (capillary blood sample,
analyzed by a gas analyzer Gem Premier 3000; reference
values  0.3–3 mmol/L); serum level of the second generation
troponin I (cTnI-Ultra) determined simultaneously with other
biomarkers (CK-MB, BNP and CRP) in the first 24–48 h af-
ter birth [enzyme-linked immunosorbent method on a Biom-
erieux mini Vidas ELFA (“enzyme-linked fluorescent as-
say”)]. For this type of analyzer in the adult population, nor-
mal values 㻌 㻌 (99. percentile) of serum level of cTnI-Ultra were
< 0.01 μg/L with coefficient of variation of 10% (from 0.01
to 0.11 μg /L) 
27. For the neonatal population, the reference
value for the second-generation cTnI is still not known,
whereas the first generation cTnI reference range is from
0.01 to 2.8 μg/L, depending on authors 
28–30; creatine kinase
MB fraction (CK-MB) level was determined by a biochemi-
cal analyzer Beckman Coulter. For such analysis, the adult
population reference range is 2–25 U/L, while for the neo-
natal population 95th percentile for healthy full-term new-
borns is 72 U/L 
10; The level of "brain" natriuretic peptide
(BNP) was determined from the same sample of blood on the
immunochemical analyzer Axsym. In the adult population
BNP reference value is < 108 pg/mL while in the neonatal
population it varies from 231.6 ± 197.5 pg/mL in the first
week of life,  to 48.449 ± 49.1 pg/mL in the later period 
31;
serum concentration of C-reactive protein (CRP) was deter-
mined by the biochemical analyzer Beckman Coulter. The
reference value 㻌 㻌 in the Clinical Center Kragujevac laboratory,
irrespective of age, is < 5 ng/mL.
To analyse of basic respondent’s clinical characteristics
we used descriptive statistics – mean and standard deviation.
To display the mean values 㻌 㻌 of biochemical markers and other
variables, whose distribution was not normal we used descrip-
tive statistics – median and quartiles. To compare the mean
values 㻌 㻌 of variables two populations were used: Mann-Whitney-
test and ANOVA. The correlation of two numerical character-
istics was examined using Spearman's and Pearson's correlation
coefficient. The suitability of numeric variables was tested us-
ing ROC (receiver operating characteristic) curves.
Results
In the group of 55 asphyxiated newborn infants there
were 31 (56.4%) males and 24 (43.6%) females. The average
gestational age (GA) was 39.5 ± 1.3 weeks and the average
birth-weight (BW) 3429 ± 571 g. All of them presented with
fetal distress syndrome and/or abnormal obstetric history.
Furthermore, all had clinical signs of cardiorespiratory and
neurological disability [i.e., Apgar score recorded at the first
minute < 4, Apgar score at the 5th minute < 7, seizures (< 48
h after birth), hypotonia or comma, hypotension and/or oli-
guria and multiorgan dysfunction with postnatal blood lac-
tate level > 3.7 mmol/L (1–6 h after birth)]. Nineteen out of
55 newborns (34.5%) were delivered by caesarean section.
Thirty-one out of 55 (56.4%) newborns required respiratory
and 23 (41.8%) pressure support; 13 (23.6%) had critical
cardiorespiratory problems or multiorgan dysfunction and
died. The median 5th minute Apgar score  in this group of
newborn infants was 5 (range 3–7), and mean value of lac-
tate levels  8.63 ± 4.43 mmol/L. Median CRP concentration
was 4.2 mg/L (range 1.9–12.1 mg/L). The median value of
CK in the same group of neonates was 1,550 U/L (range
608–4736 U/L) and the mean value of CK-MB fraction
240.7 ± 212.1 U/L. The median level of cTnI in the group of
asphyxiated newborn infants (both survived and non-
survived) was 0.08 ȝg/L (range 0.02–0.17 ȝg/L).
In the control group of 36 non-asphyxiated healthy
newborn infants there were 17 males and 19 females. The
average BW was 3,455 ± 352 g and GA 39.8 ± 1.1 weeks.
All the participants had Apgar score > 8 at 5th minute (me-
dian 9) and their lactate levels were 1.04 ± 0.36 mmol/L.
Table 1 shows the average serum concentrations of the
analyzed biochemical markers in the groups of full-term
newborns with and without perinatal asphyxia, measured
during the first two days of life. There was a statistically sig-
nificant difference in concentrations of all the investigated
biochemical markers (CRP, cTnI, CK-MB and BNP) be-
tween the examined groups of neonates.
Table 1
Average value of the analyzed biochemical markers in the observed groups
Analyzed biochemical markers Asphyxiated newborns
(n = 55)
Healthy newborns
(n = 36) p
Lactate (mmol/L), ʉ ± SD 8.63 ± 4.43 1.04 ± 0.36 0.000
C-reactive protein (mg/L) 4.20 (IQR 1.9–12.1) 2.60 (IQR 0.8–4.8) 0.017
Cardiac troponin I (μg/L) 0.08 (IQR 0.02–0.17) 0.01 (IQR 0.01–0.01) 0.000
Creatine kinase-MB (U/L), ʉ ± SD 240.69 ± 212.13 78.83 ± 39.14 0.000
B-type natriuretic peptide (pg/mL),
ʉ ± SD
993.05 ± 1259.51 278.98 ± 190.47 0.003
p – statistical significance; IQR – interquartile range.Strana 152 VOJNOSANITETSKI PREGLED Volumen 71, Broj 2
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In both groups of patients (n = 91), all the investigated
biochemical parameters (CRP, cTnI, CK-MB and BNP) cor-
related with the parameters of perinatal asphyxia (5th minute
Apgar score and lactate concentration) (Table 2). However,
in the group of full-term neonates with perinatal asphyxia,
5th minute Apgar score and lactate concentration signifi-
cantly correlated only with cTnI and CK-MB levels (Tables
2 and 3).
CTnI level negatively correlated with the 5th minute
Apgar score (unified group r = -0.637; group with PA r = -
0.318), and positively correlated with the serum lactate level
(r = 0.529 in unified group and r = 0.399 in PA group) and
the concentration of CK-MB (r = 0.507 in the unified group
and r = 0.410 in the PA group). The correlation between
cTnI and CRP was less pronounced (unified group r = of
0.345, a PA group r = 0.290), whereas there was no correla-
tion between the concentrations of cTnI and BNP (unified
group r = 0.279; group with PA r = 0.115) (Tables 2 and 3).
In the merged group of patients (n = 91) CRP (p =
0.181) and BNP (p = 0.095) there were no reliable predictors
of death. CK-MB had a borderline predictive value for a
mortality outcome (p = 0.017). Among the tested biochemi-
cal markers only the cardiac troponin I with the area under
the ROC curve of 0.896 and serum lactate levels with an area
under the ROC curve of 0.894 had a highly significant pre-
dictive value for fatal outcome (p = 0.000) (Table 4). For a
threshold of 0.135 mg/L, cTnI was a predictor of death with
sensitivity of 84.6% and specificity 85.9%.
Table 2
Correlation of perinatal asphyxia indicators with cardiac damage parameters showed by correlation coefficients (r) in the
merged group (newborns with and without perinatal asphyxia) (n = 91)
Analyzed markers Lactate CRP cTnI CK-MB BNP
Apgar scores at 5th min r = -0.839
p = 0.000
r = -0.228
p = 0.032
r = -0.637
p = 0.000
r = -0.449
p =  0.000
r = -0.341
p = 0.022
Lactate (mmol/L) – r = 0.348
p = 0.001
r = 0.529
p =  0.000
r = 0.533
p = 0.000
r = 0.613
p = 0.000
CRP (mg/L) – – r = 0.345
p = 0.001
r = 0.337
p = 0.002
r = 0.340
p = 0.021
cTnI (μg/L) – – – r = 0.507
p = 0.000
r = 0.279
p = 0.061
CK-MB (U/L) – – – – r = 0.405
p = 0.005
p – statistical significance; CRP – C-reactive protein; cTnI – cardiac troponin I; CK-MB – creatine kinase-MB; BNP – B-type natriuretic peptide.
Table 3
Correlation of indicators of perinatal asphyxia with cardiac damage parameters showed by
correlation coefficients (r) in the group with perinatal asphyxia (n = 55)
Analyzed markers Lactate CRP cTnI CK-MB BNP
Apgar score
5th min
r = -423
p = 0.000
r = -0.086
p =  0.541
r = -0.318
p = 0.019
r = -0.286
p = 0.051
r = -0.408
p = 0.148
Lactate (mmol/L) – r = 0.242
p = 0.090
r = 0.399
p = 0.004
r = 0.318
p = 0.035
r = 0.494
p = 0.073
CRP (mg/L – – r = 0.290
p = 0.033
r = 0.279
p = 0.057
r = 0.203
p = 0.469
cTnI (μg/L) – – – r = 0.410
p = 0.004
r = 0.115
p = 0.684
CK-MB (U/L) – – – – r = 0.277
p = 0.317
p – statistical significance; CRP – C-reactive protein; cTnI – cardiac troponin I; CK-MB – creatine kinase-MB; BNP – B-type natriuretic peptide.
Table 4
Analysis of serum biochemical markers after asphyxia as a predictor of death
by ROC (receiver operating characteristic) curve in the merged groups of patients (n = 91)
Statistical values Analyzed biochemical
markers AUC p Cut-off Sensitivity Specificity
Lactate (mmol/L) 0.894 0.000 8.65 83.3% 84.0%
CRP (mg/L) 0.616 0.181 5.0 61.5% 71.4%
Troponin I (μg/L) 0.896 0.000 0.135 84.6% 85.9%
CK-MB (U/L) 0.717 0.017 126 83.3% 63.9%
BNP (pg/mL) 0.791 0.095 372.45 100% 65.1%
p – statistical significance; AUC – area under the curve; CRP – C-reactive protein; cTnI – cardiac troponin I; CK-MB – creatine kinase-MB;
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Discussion
The diagnosis of myocardial damage in newborn infants
was previously based on clinical examination, suggestive
electrocardiographic or echocardiographic examinations and
increasing value CK-MB isoenzyme. Numerous studies have
shown that CK-MB isoenzyme, and particularly total creatine
kinase, cannot be regarded as specific cardiac enzymes in the
neonatal period, but the interpretation of their increasing con-
centrations in infants must be viewed with extreme caution 
32.
Major goals of neonatal studies were both to define
normal values 㻌 㻌 of cardiac biochemical markers in the neonatal
population, and to evaluate factors that may have impact on
their serum concentrations 
6–10, 28–30.
In our study the reference value of troponin I Ultra in
healthy newborn infants was 0.0183 ± 0.026; mediana 0.01
(0.01–0.01)  μg/L.  A statistically significant higher mean
concentration of cTnI and others investigated biochemical
markers of perinatal asphyxia (lactate, CRP, CK-MB and
BNP) was found in the group of asphyxiated full-term new-
born infants compared to the group of healthy full-term neo-
nates. Similar to our results, Costa et al. 
33 and Rajakumar et
al. 
34 in two separate studies found a correlation of increased
cTnT and signs of myocardial damage in newborns with PA.
Szymankiewicz et al. 
35 studied 39 asphyxiated newborn ver-
sus 44 nonasphyxiated newborns and tried to relate the cTnT
to echocardiographic findings of myocardial damage. The
cTnT was measured within 12 and 24 hours of life. Asphyxi-
ated infants had higher levels of cTnT (0.141 versus 0.087
ng/mL) nonasphyxiated infants (p < 0.01).
In asphyxiated newborns heart failure is the conse-
quence of “hypoxic-ischemic lesions or hypotensive necro-
sis” 
33, and it can accurately be assessed through measure-
ment of cardiac troponin I serum concentrations. At birth,
cardiac troponin I is not found in skeleton muscles and other
tissues, but only in the myocardium, and its level does not
change under the influence of regenerative or degenerative
processes in muscles 
30, 32, 33. Iacovidou et al. 
36 analyzed
changes in the level of cTnI in fetuses with intrauterine ar-
rest, due to chronic malnutrition and hypoxia of the fetus,
and found a correlation between cTnI levels in neonates and
pregnant women, assuming that the increase in neonatal cTnI
level is the result of transplacental cTnI transit from mother
to fetus. On the other hand, Trevisanuto et al. 
37, similar to
our results, showed a significant increment in cTnI level in
asphyxiated newborn infants. Comparing levels of cTnI in
asphyxiated full-term neonates (gestational age 34–40
weeks), with  cTnI levels  in  serum of their mothers, these
authors found no significant association, which is similar to
the results of Alexandre et al. 
38, who also founded that
transplacenar cTnI passage is not possible. Based on such
findings Trevisanuto et al. 
37, concluded that increased cTnI
level is not related to the mother, but is strictly the conse-
quence of increased fetal and neonatal production due to or-
gan lesions in perinatal asphyxia.
In the group of full-term neonates with PA we found a
significant correlation between increased serum cTnI levels
and standard clinical markers of perinatal asphyxia such as
the 5th minute Apgar score and serum lactate levels 
6, 15. The
5th minute Apgar score and serum lactate levels also posi-
tively correlated with serum CK-MB levels but less signifi-
cantly than with cTnI, similar to other authors. This is in
agreement with recently published reports showing that CK-
MB is both less specific and less sensitive in detecting car-
diac involvement and in early prediction of poor out-
come/death in neonates with PA 
10, 12, 39.
We found that cTnI is a highly sensitive and specific
marker of myocardial damage as part of terminal multi-
system failure 
8, 10, 12, 15, 16.
In recent years, an increasing number of neonatal study
is trying to determine the value of cardiac troponin I and T,
as early indicators of critically ill newborns with PA, which
would in future allow monitoring of therapeutic response and
improvement of cardioprotective strategies.
Türker et al. 
40 in their original study compared the levels
of cTnI in 109 critically ill (mechanically ventilated neonates)
with cTnI levels in the control group (48 healthy and 48 new-
born infants requiring only the first stage of intensive care
unit). According to the results of these authors in a group of
critically ill, mechanically ventilated infants, there was a sig-
nificant increase in cTnI (median 1.4 ng/mL, the min. 0 to
max. 13.0 ng/mL;  p < 0.001), compared to the control group
(median 0, min from 0 to max. 1.84 ng/mL). Also in the group
of critically ill children with fatal outcome there has been a
significant increase in cTnI (p < 0.001), (6.6 ng/mL; 1.3–13.0
ng/mL) compared to the patients who survived (1.3 ng/mL; 0–
8.0 ng/mL). Reciver-operator curve showed that early increase
in cTnI could be a sensitive predictor of death in critically ill
newborns with the confidence interval of 96%.
Similar to other authors, we found an association of in-
creased cTnI values with several variables related to illness
severity. A statistically significant higher mean concentration
of cTnI was associated with the need of respiratory support:
0.11 μg/L (0.04–0.18); p = 0.039 and to the use of inotropic
drugs: 0.15 μg/L (0.06–0.56); p = 0.006, compared to the
group without cardio-respiratory support: 0.01 μg/L (0.01–
0.04). The results of our study suggest that early increase in
cTnI could be used as an important prognostic marker, since
serum cTnI > 0.135 mg/L predicted a mortality outcome with
sensitivity of 84.6% and specificity 85.9% 
40, 41.
CRP, as a non-specific indicator of tissue damage 
42,
and BNP, as insufficiently sensitive indicator of perinatal as-
phyxia, neither correlated with 5th minute Apgar score and
serum lactate levels, nor were reliable predictors of mortality
outcome in neonates with PA,  in our study.  One-time blood
samples in a wide interval of 24–48 h could have a limiting
effect on results analysis according to the different period of
elimination of observed biochemical markers 
43. On the other
hand, such findings could be explained by the fact that BNP
is secreted primarily from the myocardium of heart chambers
in response to pressure/volume overload
 1, 2, 13, while the in-
crease in cTnI is the result of hypoxia and/or myocardial is-
chemia 
1, 3, 5, 29, 33, 43. Heart failure is a complex clinical syn-
drome and a single biochemical marker, such as BNP, may
not reflect all of its features. Measurement of both serum
BNP levels, as markers of cardiac load, and cTnI levels, asStrana 154 VOJNOSANITETSKI PREGLED Volumen 71, Broj 2
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markers of myocardial damage, could open new perspectives
in diagnosis, prognosis and monitoring of critically ill as-
phyxiated newborns with heart failure 
44.
Conclusion
Cardiac troponin I, a highly specific and sensitive
marker of myocardial damage, can be used as a prognostic
marker of perinatal asphyxia in full-term newborn infants.
Increase in cardiac troponin I > 0.135 mg/L in the first 24–48
h after birth may predict fatal outcome with sensitivity of
84.6% and specificity 85.9%.
Creatinine kinase MB fraction is both sensitive and
specific marker of myocardial damage, but its predictive
value is less significant than cTnI.
C-reactive protein is not sensitive indicator of perinatal
asphyxia and, accordingly, its increase in the serum cannot
be used for early prediction of outcome.
The increase in serum BNP levels in the population of
full-term newborns, in our study did not appear to be a reli-
able predictor of perinatal asphyxia. Further studies on more
patients are necessary to assess its predictive capacity in
terms of mortality outcome in full-term neonates with peri-
natal asphyxia.
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